Literature DB >> 16098566

Early identification of acute myocardial infarction by activated protein C--protein C inhibitor complex.

Pallonji Bhiladvala1, Karin Strandberg, Johan Stenflo, Johan Holm.   

Abstract

INTRODUCTION: Increased coagulation activity due to coronary thrombosis in a ruptured plaque should result in activation of the protein C anticoagulant system with formation of complexes between activated protein C (APC) and the protein C inhibitor (PCI), which reflects coagulation activity. We hypothesized that elevated APC-PCI concentration might allow earlier detection of ongoing myocardial infarction than traditional biochemical markers. We have evaluated a newly devised immunofluorimetric assay for measuring plasma concentration of APC-PCI complexes among patients with suspected acute coronary syndrome.
MATERIALS AND METHODS: Blood samples were taken from 340 patients (median 71 years, range 31-97) with suspected acute coronary syndrome at first presentation in the emergency department. Electrocardiogram was recorded and APC-PCI, Troponin I and Creatine kinase-MB concentrations were repeatedly measured 3 times at 6 h interval.
RESULTS: The 74 patients who were eventually diagnosed with myocardial infarction had a higher median level of APC-PCI complex than those without myocardial damage; 0.27 vs. 0.20 microg/L (p = 0.001). In a multivariate regression model, APC-PCI level in the fourth quartile (>0.32 microg/L) independently predicted myocardial infarction with an odds ratio of 3.7 (95% CI 1.4-9.6, p < 0.01).
CONCLUSION: Early APC-PCI elevation can be detected among patients with a normal first Troponin I and non-ST-elevation myocardial infarction and provides additional risk assessment in acute coronary syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098566     DOI: 10.1016/j.thromres.2005.06.020

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  APC-PCI complex levels for screening of AAA in patients with peripheral atherosclerosis.

Authors:  Moncef Zarrouk; Kave Keshavarz; Bengt Lindblad; Anders Gottsäter
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

2.  Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation.

Authors:  Johan Undén; Karin Strandberg; Jan Malm; Eric Campbell; Lars Rosengren; Johan Stenflo; Bo Norrving; Bertil Romner; Arne Lindgren; Gunnar Andsberg
Journal:  J Neurol       Date:  2009-02-09       Impact factor: 4.849

3.  Is protein C inhibitor antithrombotic and protective in pulmonary hypertension?

Authors:  L M Beaulieu; F C Church
Journal:  J Thromb Haemost       Date:  2006-09-15       Impact factor: 16.036

4.  Plasma levels of thrombin and activated protein C in patients with acute myocardial Infarction: An observational study.

Authors:  Tobias Becher; Robert Schimanski; Jens Müller; Stefan Baumann; Selina Klenantz; Bernd Pötzsch; Dirk Lossnitzer
Journal:  Int J Cardiol Heart Vasc       Date:  2022-07-30

Review 5.  Serpins in thrombosis, hemostasis and fibrinolysis.

Authors:  J C Rau; L M Beaulieu; J A Huntington; F C Church
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.